Business Description
Cytokinetics is a US-based drug development company focused on creating medicines that target muscle function to treat serious heart and muscle diseases. Its lead product, MYQORZO, is an approved oral treatment for a condition where the heart muscle becomes abnormally thick and obstructed, and the company has several other drugs in various stages of clinical testing that aim to address different forms of heart failure. Founded in 1997 and based in South San Francisco, Cytokinetics is working to build a portfolio of treatments for patients with few existing options.
